3,4-dihydroxybenzohydroxamic acid has been researched along with hydroxyurea in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.67) | 18.7374 |
| 1990's | 4 (26.67) | 18.2507 |
| 2000's | 7 (46.67) | 29.6817 |
| 2010's | 3 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Elford, HL; van't Riet, B; Wampler, GL | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Cory, JG; Elford, HL; Tihan, T | 1 |
| Chitambar, CR; Elford, HL; Myette, MS | 1 |
| Birch, NJ; Elford, HL; Gallicchio, VS; Greenberg, RN; Mayhew, CN; Phillips, JD | 1 |
| Smart, T | 1 |
| Ahmed, MM; Chendil, D; Elford, HL; Gallicchio, VS; Greenberg, RN; Mampuru, LJ; Mayhew, CN; Phillips, JD | 1 |
| Cibull, ML; Elford, HL; Gallicchio, VS; Mayhew, CN; Phillips, JD | 1 |
| Duvall, W; Elford, HL; Gallicchio, VS; Hagan, E; Inayat, MS; Mayhew, CN; Sumpter, LR; Yost, EE | 1 |
| Cibull, M; Elford, HL; Gallicchio, VS; Inayat, M; Mayhew, CN; Phillips, JD; Sumpter, R | 1 |
| Bonar, MM; Bush, CA; Cardounel, AJ; Cui, H; Elford, HL; Henry, JC; Kearns, PN; Martin, MV; Mutchler, MM; Orsini, AR; Zweier, JL | 1 |
| Pagano, JS; Raab-Traub, N; Wakisaka, N; Yoshizaki, T | 1 |
| Bergdall, VK; Cardounel, AJ; Elford, HL; Gallaugher, LD; Henry, JC; Kearns, PN | 1 |
| Bhave, S; Elford, H; McVoy, MA | 1 |
| Caslin, HL; Elford, HL; Kolawole, EM; McLeod, JJA; Paranjape, A; Qayum, AA; Ryan, JJ; Spence, AJ; Taruselli, MT | 1 |
15 other study(ies) available for 3,4-dihydroxybenzohydroxamic acid and hydroxyurea
| Article | Year |
|---|---|
Synthesis of hydroxy- and amino-substituted benzohydroxamic acids: inhibition of ribonucleotide reductase and antitumor activity.
Topics: Animals; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Hydroxamic Acids; Hydroxyurea; In Vitro Techniques; Leukemia L1210; Liver Neoplasms, Experimental; Mice; Ribonucleotide Reductases; Structure-Activity Relationship | 1979 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Studies on the mechanisms of inhibition of L1210 cell growth by 3,4-dihydroxybenzohydroxamic acid and 3,4-dihydroxybenzamidoxime.
Topics: Animals; Antineoplastic Agents; Cell Division; Cell Line; Cytidine; Deoxyribonucleotides; Hydroxamic Acids; Hydroxyurea; Kinetics; Leukemia L1210; Mice; Oximes; Ribonucleotide Reductases | 1991 |
Interaction of gallium nitrate with other inhibitors of ribonucleotide reductase: effects on the proliferation of human leukemic cells.
Topics: Antineoplastic Agents; Benzamidines; Cell Division; Deoxycytidine; Drug Synergism; Enzyme Inhibitors; Gallium; Gemcitabine; Humans; Hydroxamic Acids; Hydroxyurea; Oximes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Ribonucleotide Reductases; Tumor Cells, Cultured | 1998 |
In vivo and in vitro comparison of the short-term hematopoietic toxicity between hydroxyurea and trimidox or didox, novel ribonucleotide reductase inhibitors with potential anti-HIV-1 activity.
Topics: Acquired Immunodeficiency Syndrome; Anemia; Animals; Anti-HIV Agents; Benzamidines; Cells, Cultured; Colony-Forming Units Assay; Enzyme Inhibitors; Female; Femur; Hematopoiesis; Hematopoietic Stem Cells; Humans; Hydroxamic Acids; Hydroxyurea; In Vitro Techniques; Lymphocytes; Macrophages; Mice; Mice, Inbred C57BL; Neutrophils; Organ Size; Ribonucleotide Reductases; Spleen | 1999 |
Beyond hydroxyurea.
Topics: Animals; Antiviral Agents; Benzamidines; Dipyridamole; Disease Models, Animal; Floxuridine; Fluorouracil; Humans; Hydroxamic Acids; Hydroxyurea; Mice; Murine Acquired Immunodeficiency Syndrome; Ribonucleotide Reductases | 1995 |
Suppression of retrovirus-induced immunodeficiency disease (murine AIDS) by trimidox and didox: novel ribonucleotide reductase inhibitors with less bone marrow toxicity than hydroxyurea.
Topics: Animals; Benzamidines; Bone Marrow Cells; DNA, Viral; Female; Femur; Free Radical Scavengers; Hematopoietic Stem Cells; Hydroxamic Acids; Hydroxyurea; Hypergammaglobulinemia; Leukemia Virus, Murine; Leukemia, Experimental; Mice; Mice, Inbred C57BL; Murine Acquired Immunodeficiency Syndrome; Proviruses; Retroviridae Infections; Ribonucleotide Reductases; Spleen; Splenomegaly; Tumor Virus Infections | 2002 |
Short-term treatment with novel ribonucleotide reductase inhibitors Trimidox and Didox reverses late-stage murine retrovirus-induced lymphoproliferative disease with less bone marrow toxicity than hydroxyurea.
Topics: Animals; Antiviral Agents; Benzamidines; Blood Cell Count; Body Weight; Bone Marrow; Hydroxamic Acids; Hydroxyurea; Leukemia Virus, Murine; Lymphoproliferative Disorders; Mice; Spleen; Time Factors | 2002 |
In vivo examination of hydroxyurea and the novel ribonucleotide reductase inhibitors trimidox and didox in combination with the reverse transcriptase inhibitor abacavir: suppression of retrovirus-induced immunodeficiency disease.
Topics: Animals; Antiviral Agents; Benzamidines; Bone Marrow Cells; Dideoxynucleosides; Disease Models, Animal; Drug Therapy, Combination; Hematopoietic Stem Cells; Hydroxamic Acids; Hydroxyurea; Mice; Mice, Inbred C57BL; Murine Acquired Immunodeficiency Syndrome; Ribonucleotide Reductases; Spleen; Splenomegaly | 2004 |
Combination of inhibitors of lymphocyte activation (hydroxyurea, trimidox, and didox) and reverse transcriptase (didanosine) suppresses development of murine retrovirus-induced lymphoproliferative disease.
Topics: Animals; Antiviral Agents; B-Lymphocytes; Benzamidines; Didanosine; Drug Therapy, Combination; Enzyme Inhibitors; Female; Hydroxamic Acids; Hydroxyurea; Leukemia Virus, Murine; Leukemia, Experimental; Lymphocyte Activation; Mice; Mice, Inbred C57BL; Murine Acquired Immunodeficiency Syndrome; Retroviridae Infections; Reverse Transcriptase Inhibitors; Ribonucleotide Reductases; Treatment Outcome; Tumor Virus Infections | 2005 |
Inhibition of ribonucleotide reductase reduces neointimal formation following balloon injury.
Topics: Animals; Catheterization; Cell Movement; Cell Proliferation; Coronary Restenosis; Coronary Vessels; Enzyme Inhibitors; Flow Cytometry; Hydroxamic Acids; Hydroxyurea; Male; Muscle, Smooth, Vascular; Rats; Rats, Wistar; Ribonucleotide Reductases | 2005 |
Ribonucleotide reductase inhibitors enhance cidofovir-induced apoptosis in EBV-positive nasopharyngeal carcinoma xenografts.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma; Cidofovir; Cytosine; Drug Interactions; Enzyme Inhibitors; Epstein-Barr Virus Infections; Humans; Hydroxamic Acids; Hydroxyurea; Mice; Mice, Nude; Nasopharyngeal Neoplasms; Organophosphonates; Ribonucleotide Reductases; Transplantation, Heterologous; Tumor Cells, Cultured | 2005 |
Ribonucleotide reductase inhibitors reduce atherosclerosis in a double-injury rabbit model.
Topics: Animals; Atherosclerosis; Disease Models, Animal; Enzyme Inhibitors; Hydroxamic Acids; Hydroxyurea; Rabbits; Ribonucleotide Reductases | 2009 |
Ribonucleotide reductase inhibitors hydroxyurea, didox, and trimidox inhibit human cytomegalovirus replication in vitro and synergize with ganciclovir.
Topics: Antiviral Agents; Benzamidines; Cell Line; Cytomegalovirus; Cytomegalovirus Infections; Drug Synergism; Ganciclovir; Humans; Hydroxamic Acids; Hydroxyurea; Inhibitory Concentration 50; Ribonucleotide Reductases | 2013 |
Didox (3,4-dihydroxybenzohydroxamic acid) suppresses IL-33-induced cytokine production in primary mouse mast cells.
Topics: Acetylcysteine; Animals; Bone Marrow Cells; Chemokine CCL3; Female; Gene Expression Regulation; Genes, Reporter; Hydroxamic Acids; Hydroxyurea; Immunosuppressive Agents; Interleukin-13; Interleukin-33; Lipopolysaccharides; Luciferases; Male; Mast Cells; Mice; Mice, Inbred C57BL; NF-kappa B; Primary Cell Culture; Signal Transduction; Transcription Factor AP-1; Tumor Necrosis Factor-alpha | 2017 |